Sodium phenylbutyrate slow-release - LUNAMeD AG
Alternative Names: 4-PB-D-alanin; 4PHENYL-BUTYRATE; LU-901; LunaphenLatest Information Update: 03 Sep 2021
At a glance
- Originator LUNAMeD AG
- Class Antineoplastics; Electrolytes; Phenylbutyrates; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Huntington's disease; Major depressive disorder; Primary sclerosing cholangitis; Prostate cancer; Psoriasis; Solid tumours; Tinnitus; Ulcerative colitis; Varicose veins; Vulvovaginitis
Most Recent Events
- 03 Sep 2021 Discontinued - Clinical-Phase-Unknown for Huntington's disease in Switzerland (PO) (LUNAMeD AG's website, August 2021)
- 03 Sep 2021 Discontinued - Clinical-Phase-Unknown for Major depressive disorder in Switzerland (PO) (LUNAMeD AG's website, August 2021)
- 03 Sep 2021 Discontinued - Clinical-Phase-Unknown for Primary sclerosing cholangitis in Switzerland (PO) (LUNAMeD AG's website, August 2021)